Public Health Research Institute, New Jersey Medical School, UMDNJ, 225 Warren Street, Newark, NJ 07103, USA.
J Antimicrob Chemother. 2010 Mar;65(3):520-4. doi: 10.1093/jac/dkp486. Epub 2010 Jan 12.
Quinolone-mediated death of Escherichia coli has been proposed to occur by two pathways. One is blocked by inhibitors of protein synthesis; the other is not. It is currently unknown how these two pathways fit with the recent observation that hydroxyl radical accumulation is associated with quinolone lethality.
E. coli was treated with thiourea plus 2,2'-bipyridyl to block hydroxyl radical accumulation, and the effect on quinolone lethality was measured for quinolones that distinguished the two lethal pathways: oxolinic acid requires protein synthesis to kill E. coli, while PD161144, a C-8-methoxy fluoroquinolone, does not. The lethal activity of another fluoroquinolone, moxifloxacin, was partially blocked by the presence of chloramphenicol, an inhibitor of protein synthesis. That feature made it possible to determine whether the effects of chloramphenicol and thiourea plus 2,2'-bipyridyl were additive.
Lethal activity of oxolinic acid was completely blocked by thiourea plus 2,2'-bipyridyl and by chloramphenicol. In contrast, PD161144 lethality was unaffected by these treatments. With moxifloxacin, both chloramphenicol and thiourea plus 2,2'-bipyridyl separately exhibited the same partial inhibition of quinolone lethality. No additivity in protection from moxifloxacin lethality was observed when thiourea, 2,2'-bipyridyl and chloramphenicol were combined and compared with the effect of chloramphenicol or thiourea plus 2,2'-bipyridyl used separately.
Inhibitor studies indicated that hydroxyl radical action contributes to quinolone-mediated cell death occurring via the chloramphenicol-sensitive lethal pathway but not via the chloramphenicol-insensitive pathway.
已提出喹诺酮类药物介导的大肠埃希菌死亡由两种途径发生。一种途径被蛋白质合成抑制剂阻断,另一种途径则不受影响。目前尚不清楚这两种途径与最近观察到的羟自由基积累与喹诺酮类药物致死性相关的情况如何吻合。
用硫脲加 2,2'-联吡啶处理大肠埃希菌,以阻断羟自由基的积累,并测定这两种喹诺酮类药物区分的两种致死途径的喹诺酮类药物的致死作用:奥索林酸需要蛋白质合成才能杀死大肠埃希菌,而 PD161144(一种 C-8-甲氧基氟喹诺酮)则不需要。另一种氟喹诺酮莫西沙星的致死活性被蛋白质合成抑制剂氯霉素部分阻断。这一特征使得能够确定氯霉素和硫脲加 2,2'-联吡啶的作用是否具有加性。
硫脲加 2,2'-联吡啶和氯霉素完全阻断了奥索林酸的致死活性。相比之下,这些处理对 PD161144 的致死作用没有影响。对于莫西沙星,氯霉素和硫脲加 2,2'-联吡啶分别单独使用时,对喹诺酮类药物致死性均表现出相同的部分抑制作用。当将硫脲、2,2'-联吡啶和氯霉素联合使用并与氯霉素或硫脲加 2,2'-联吡啶单独使用的效果进行比较时,没有观察到对莫西沙星致死性的保护作用具有加性。
抑制剂研究表明,羟自由基作用有助于通过氯霉素敏感的致死途径而不是通过氯霉素不敏感的途径发生的喹诺酮类药物介导的细胞死亡。